E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT) |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042875 |
E.1.2 | Term | Synovitis villonodular |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To measure the effectiveness of 12 weeks (3 months) of nilotinib treatment in preventing disease progression by measuring overall response (Complete response + Partial Response + Stable disease) according to Response Evaluation Criteria In Solid Tumours – RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery. |
|
E.2.2 | Secondary objectives of the trial |
Second, the study will measure the effectiveness of 24 weeks (6 months) of nilotinib treatment in preventing disease progression by measuring overall response (Complete response + Partial Response + Stable disease) according to Response Evaluation Criteria In Solid Tumours – RECIST version 1.1)in the same group of patients
The study will also assess the efficacy of nilotinib according to: - The objective tumour response rate (Complete response + Partial Response according to RECIST version 1.1) after 12 weeks of treatment - The duration of treatment response - The best overall response obtained during the study - The progression-free survival (PFS) - The time to progression (TTP) - The time to treatment failure (TTF) - The proportion of patients with an operable tumour after nilotinib treatment according to investigator evaluation - The description of concomitant treatments use - The correlation between trough levels of nilotinib and objective tumour response - To assess |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Title: Complementary biologic study An exploratory objective of the study will be to study the relationship between the objective tumour response and the following tumour characteristics (tissues collected in a prior surgery, or by biopsy, upon specific acceptance by the patient): - Presence of COL6A3/CSF1 fusion gene - Presence of M-CSF, CSF1R, KIT, PDGFRA and B on immunohistochemistry - Presence of phosphorylated c-fms on tumour samples - Activation of the PI3K/Akt/mTor pathway, presence of activating mutations of ras, and other potential molecular alterations |
|
E.3 | Principal inclusion criteria |
Age ≥18 years Histologically confirmed diagnosis of inoperable progressive or relapsing PVNS or resectable tumour requiring mutilating surgery. Demonstrated progressive disease in the last 12 months. At least one measurable site of disease on MRI/CT scan according to RECIST criteria based on investigators assessment WHO Performance status of 0,1,or 2 Adequate organ, electrolyte and marrow function as defined in protocol. Prior adequate physical examination including weight, height, ECOG Performance Status and vital signs (systolic and diastolic blood pressure, heart rate after at least 5 minutes in supine position) Signed written informed consent form Covered by a medical insurance( in applicable countries - not applicable to UK) |
|
E.4 | Principal exclusion criteria |
Pregnant or lactating female or female of child bearing potential not employing adequate contraception during the study and for up to three months following termination of the study. Known hypersensitivity to nilotinib or to any of the excipients, galactose intolerance, lactase deficiency of or glucose-galactose malabsorption prior to enrolment. Acute or chronic uncontrolled liver disease, or severe renal disease Impaired cardiac function as defined by protocol Patient with family history of long QT syndrome, or unexplained syncope or unexplained sudden death Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g.uncontrolled diabetes, active or uncontrolled infection, history of pancreatitis History of non-compliance to medical regimens Concomitant treatment with medical products that induce CYP3A4(e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or St.Johns Wort),or that inhibit the CYP3A4 activity (e.g.ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin) Concomitant treatment with warfarin Concomitant treatment with anti-arrhythmic drug or medication that prolongs the QT interval Prior treatment with imatinib except if no progression was demonstrated |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure will be the non progression rate after 12 weeks of treatment, based on the response evaluated by CT/MRI according to RECIST criteria and validated by central review committee. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary efficacy endpoint: Non progression rate after 24 weeks (6 months) of treatment, based on the response evaluated by CT scan or MRI according to RECIST criteria (RECIST version 1.1). Other secondary efficacy endpoints: - Objective tumour response according to RECIST version 1.1 (CR and PR) after 12 weeks of treatment - Duration of response - Best overall response - Progression-free survival - Time to progression - Time to treatment failure - Non progression rate after 12 weeks of treatment, based on the response evaluated locally by the investigator in charge using CT scan or MRI and according to RECIST criteria (RECIST version 1.1) - Proportion of patients with an operable tumour after nilotinib exposure according to investigator evaluation - Concomitant treatment use during the study - Correlation between trough level of nilotinib at 6 weeks and 12 weeks and objective tumour response |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the end of the clinical study of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |